A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors.
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2018
Price : $35 *
At a glance
- Drugs Imetelstat (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 03 Aug 2018 Planned primary completion date changed from 1 Mar 2016 to 25 Mar 2016.
- 03 Aug 2018 Planned initiation date changed from 1 Jan 2014 to 30 Jun 2014.
- 07 Mar 2014 According to the ClinicalTrials.gov record, status changed from not yet recruiting to suspended.